MedAssets pullback a buying opportunity, says Jefferies Jefferies believes MedAssets' core business is back on track following yesterday's analyst day and it recommends buying the stock on the recent pullback. The firm has a Buy rating on the name with a $30 price target.
Healthways, MedAssets partner in new five-year agreement Healthways (HWAY) has partnered with MedAssets (MDAS) to expand patient access to the Dr. Dean Ornish Program for Reversing Heart Disease. Under the five-year agreement, Healthways has contracted with MedAssets as its sales partner to accelerate deployment of the Ornish Reversal Program to hospitals, health systems and physician organizations. The Ornish Reversal Program is the most scientifically proven platform in lifestyle medicine for treating and reversing heart disease and other chronic conditions.